Cabometyx gets NICE recommendation in renal cell carcinoma
French drugmaker Ipsen (Euronext: IPN) announced on Friday that it has received a recommendation from the National Institute of Care Excellence (NICE) for National Health Service (NHS) funding of Cabometyx (cabozantinib) for use in adult patients with advanced renal cell carcinoma (RCC).
The approval, based on results from the Phase II CABOSUN study which showed Cabometyx increasing survival times among patients when compared to Pfizer's (NYSE: PFE) Sutent (sunitinib), comes two years after the Medicines and Healthcare products Regulatory Agency (MHRA) designated Cabometyx a "promising innovative medicine" and three months after Ipsen's kidney cancer therapy was approved by the European Commission.
Matthew Hickling, medical director of Ipsen UK and Ireland commented on the announcement, saying: "This decision is very positive news for advanced RCC patients that don’t have time to wait and can now access cabozantinib earlier in their treatment pathway."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze